On Innovative Behavior of State-owned Pharmaceutical Enterprises from the Perspective of Ownership Structure Reform

Guangping Wang,Shengyi Shi,Yanfei Huo,Bin Jiang
DOI: https://doi.org/10.16153/j.1002-7777.2018.02.003
2018-01-01
Abstract:Objective: To analyze the leading and exemplary role of the state-owned pharmaceutical enterprises in the implementation of national innovation and development strategies on the basis of their particularity in the economy, social responsibility and political task, and to put forward the methods of enhancing the innovative capacity of the state-owned pharmaceutical enterprises. Methods: Based on the analysis of medical ownership reform and innovation policy, the Malmquist index of Data Envelopment Analysis (DEA) was used to dynamically analyze the innovation performance of state-owned pharmaceutical enterprises. The panel data model was used to do the empirical analysis of the innovation performance of state-owned pharmaceutical enterprises. Results and Conclusion: The state-owned enterprises have fulfilled good achievement in innovation in the subfield of biological products manufacturing industry. The State-owned enterprises are the main force to achieve pharmaceutical economic growth of China, but the phenomenon of excessive concentration and surplus of research and development resources still exist. The way to enhance innovation ability of the state-owned pharmaceutical enterprises consists of the market radiating and integrating, micro-cooperation, organizational restructuring and cross-regional integration, and so on.
What problem does this paper attempt to address?